New Gut-Targeted drug tested in healthy people for first time
NCT ID NCT06835296
First seen Jan 11, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This early-stage study tested a new oral drug, YUQ-A1007, in 47 healthy adults to see if it is safe and how the body processes it. The drug is designed to treat inflammatory bowel disease (IBD) by targeting the gut. Since this is the first time the drug is given to humans, the main goal was to check for side effects and measure drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801, United States
Conditions
Explore the condition pages connected to this study.